AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01887678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traumeel® / Zeel® Injectable Solution
Description: Injection volume is 4.2 mL for active study medication (2.0 mL Zeel plus 2.2 mL Traumeel in one IA injection) on treatment days 1, 8 and 15.
Study NCT01887678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is an injection of Saline
Study NCT01728571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Study NCT01728571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fish oil
Study NCT01426347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ergocalciferol
Description: Ergocalciferol 50,000 IU per week for 16 weeks
Study NCT01727869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1400
Study NCT01727869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study NCT01727869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT01774136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced HIV and MCH training for CHW
Study NCT03833895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: 0.05ug/kg/min Norepinephrine during Cesarean Section Operation
Study NCT03833895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: 0.25ug/kg/min phenylephrine during Cesarean Section Operation
Study NCT03833895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringer's Solution
Description: 3 ml/kg/min of LR was administrated according to standard weight.
Study NCT00736411 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: acupuncture
Description: 16 treatments over 8 weeks
Study NCT00736411 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF
Description: one 4 week IVF cycle
Study NCT01715207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Study NCT01715207 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atenolol
Study NCT01715207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Study NCT02590471 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angioplasty with stenting of the femoral artery
Description: A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon extpandable or self-expanding) of all the extension is mounted.~Medical therapy includes aspirin (acid acetylsalicylic) prescription before the procedure (160 - 300 mg/d), beginning from minimum per day and heparin (heparin sodium) injection during the procedure (5000 U iv). After the procedure aspirin (acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix (clopidogrel) in dose 75/d should be prescribed within 3 months.
Study NCT02590471 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angioplasty with stenting of the femoral artery, supplemented by fasciotomy in Hunter's channel
Description: Standard endovascular stenting of femoral artery. The exposure is carried out to the distal part of superficial femoral artery when it lives Hunter's canal and the first portion of popliteal artery. Intermuscular vastoadductoria sept is dissected and the following arteries are ligated and dissected: а. superior medialis genus, а. superior lateralis genus.~Medical therapy includes aspirin (acid acetylsalicylic) prescription before the procedure (160 - 300 mg/d), beginning from minimum per day and heparin (heparin sodium) injection during the procedure (5000 U iv). After the procedure aspirin (acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix (clopidogrel) in dose 75/d should be prescribed within 3 months.
Study NCT00445575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
Study NCT00445575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
Study NCT04455607 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: perturbation training
Description: A Randomized control trial we will compare two perturbation motor learning paradigms with different challenge level of the practice condition (i.e. blocked practice vs random practice). According to motor learning theory we hypothesize that a) healthy older adults will benefit more from random practice. The purpose of this stage is to investigate the effects of task practice order (random vs blocked) on motor learning (i.e. responding to perturbations during walking) in older adults. According to motor learning theory we hypothesize that a) healthy older adults will benefit more from the random motor learning approach as compared to using blocked practice.
Study NCT04455607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: perturbation training
Description: A Randomized control trial we will compare two perturbation motor learning paradigms with different challenge level of the practice condition (i.e. blocked practice vs random practice). According to motor learning theory we hypothesize that a) healthy older adults will benefit more from random practice. The purpose of this stage is to investigate the effects of task practice order (random vs blocked) on motor learning (i.e. responding to perturbations during walking) in older adults. According to motor learning theory we hypothesize that a) healthy older adults will benefit more from the random motor learning approach as compared to using blocked practice.
Study NCT02496598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In Vitro Follicle Activation (IVA)
Description: Laparoscopic removal of ovarian tissue, followed by in vitro activation of dormant ovarian follicles and autografting back to the patient for follicle growth and egg retrieval.
Study NCT02496598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follicle Activation
Description: Ovarian cortical pieces will be treated in vitro with a PTEN activator (bpV(hopic)) and a PI3K inhibitor (740YP) in vitro to activate primordial ovarian follicles, prior to autografting.
Study NCT02335645 — intervention group
Intervention type: OTHER
Intervention: Body Weight Supported Treadmill Use of Patients with ACL Reconstruction
Description: Standard ACL protocol will be followed throughout the treatment of each patient. The only variance from treatment will be using body weight supported treadmill and video gait analysis to help guide treatment.~The first analysis will be performed at week 6 after surgery. Motion capture sensors will be placed on the patient at different anatomical positions. The patient will then run in a body weight supported treadmill. During this run, video capture will be performed and later analyzed to determine biomechanical kinematics.~Based on findings of video gait analysis, exercise progression will be altered to improve deficits found. This process will be repeated at week 8 of rehabilitation in the body weight supported treadmill.~At week 10 and 12, the patient will shift treatment from the body weight supported treadmill, to a standard treadmill. The process will be repeated using the same anatomical landmarks and video capture.
Study NCT02230462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Viewing of cancer excision defect
Description: Patients will be invited to view their cancer excision defect, with the aid of a mirror, prior to its reconstruction.
Study NCT01688310 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gomco Clamp with Tissue Adhesive
Description: According to WHO (2011), the Gomco clamp has ...an impeccable safety record. In the USA, where it is estimated that well over 1 million neonates are circumcised each year, the Gomco clamp has become the leading instrument used to perform non-ritual male circumcision. Tissue adhesive is widely used in multiple areas of medicine; specifically, multiple observational studies and RCTs have shown cyanoacrylate tissue adhesives to be superior to suture closure in VMMC.
Study NCT01688310 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgical circumcision
Description: The World Health Organization, in its Manual for Male Circumcision under Local Anaesthesia, describes three open surgical techniques (forceps assisted, dorsal slit and sleeve technique), all three of which involve (a) exposure of subcutaneous tissues and (b) suturing for hemostasis and for skin closure.
Study NCT02121912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FPH Pilairo Q CPAP mask
Description: CPAP nasal-pillow mask
Study NCT02121912 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Any other market released nasal or nasal-pillow CPAP mask
Description: Any other market released nasal or nasal-pillow CPAP mask
Study NCT02842983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: conventional management plus esmolol infusion
Study NCT03739372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialized tumor board recommendation
Description: Based on the molecular profile, the specialized tumor board will determine an individualized treatment recommendation for each patient using up to four FDA approved drugs. In special circumstances, Investigational new drug (IND) study agents may be used.
Study NCT03667937 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CUTIMED
Description: Hydrophobic Dressing
Study NCT03667937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AQUACEL silver
Description: Silver Dressing
Study NCT01190722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: 120 mg once daily for the 1st 6 postoperative days
Study NCT01190722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: 50 mg oral 3 times daily the 1st 6 postoperative days
Study NCT02132715 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Study NCT02132715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KAATSU exercise
Study NCT04643093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin
Description: Pitavastatin, QD
Study NCT04643093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe, QD
Study NCT04643093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1PC111
Description: 1PC111, QD
Study NCT00311246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Subjects will give themselves a dose of Adalimumab at 40 mg/every week by subcutaneous injection for a total of 45 weeks.
Study NCT01466790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 will be administered as one oral capsule of 150 mg once a day.
Study NCT01466790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-7977 (GS7977)
Description: PSI-7977 (GS7977) will be administered as oral tablets (2 tablets of 200 mg for Cohort 1 and 1 tablet of 400 mg for Cohort 2) once a day.
Study NCT01466790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin will be administered according to body weight. For patients with body weight less than 75 kg daily dose (1000 mg) will be administered as 400 mg (2 oral tablets of 200 mg) in the morning and 600 mg (3 oral tablets of 200 mg) in the evening. Body weight more than or equal to 75 kg daily dose (1200 mg) will be administered as 600 mg twice a day (3 tablets of 200 mg per intake, morning and evening).
Study NCT01728571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 placebo
Study NCT00356759 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times
Description: Warfarin is dosed according to INR to maintain INR 2.0-3.0 or for mechanical mitral valves or mechanical aortic valves with atrial fibrillation INR 2.5-3.5
Study NCT00936598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem
Description: Participants will receive the FDA approved dose of zolpidem, (10 mg for women \<65; 5 mg for women = or > 65 years) during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.
Study NCT00936598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: Participants will receive placebo (sugar) pills during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.
Study NCT02398032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP nasal
Description: During the night
Study NCT02398032 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham CPAP nasal
Description: During the night
Study NCT02386839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIGF-1/rhIGFBP-3
Description: Participants who received rhIGF-1/rhIGFBP-3 in study ROPP-2008-01 (NCT01096784) will be enrolled to this study. No investigational product will be administered in this study.
Study NCT02405897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cup forceps
Description: In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using cup forceps
Study NCT02405897 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alligator forceps
Description: In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using alligator forceps
Study NCT02280512 — intervention group
Intervention type: DEVICE
Intervention: elderly with fractures
Description: hemodynamic monitoring with NICOM and tissue perfusion monitoring with NIRS
Study NCT03893110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical stabilization of the spine due to primary and secondary spinal tumors
Description: Posterior instrumentation with pedicle screw system
Study NCT03893110 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical stabilization of the spine due to primary and secondary spinal tumors
Description: Posterior instrumentation with pedicle screw system
Study NCT01939301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Nitric Oxide
Description: Nitric Oxide + oxygen
Study NCT01939301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: Nitrogen + Oxygen
Study NCT02201901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg tablets administered orally once daily
Study NCT02201901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT01654068 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conformal High Dose Intensity Modulated Radiation Therapy
Description: Conformal High Dose Intensity Modulated Radiation Therapy 14-16Gy single fraction dosing using 6MV photons
Study NCT00495092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine from 300 mg/d to 1200 mg/d or 15 mg/kg/d
Study NCT00495092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biperiden
Description: Biperiden 2-4 mg/d p.o.
Study NCT00495092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo + Placebo
Study NCT01611961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT-LM
Description: Intravenous infusion, Upto 6 dose levels have been studied i.e. 45, 60, 75, 90 105,and 120 mg/m2, Every 3 weeks.
Study NCT01611961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Intravenous infusion, 3 dose levels：60, 75, and 90 mg/m2, Every 3 weeks
Study NCT04306146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAD-9303
Description: Capsules filled with CAD-9303 from 3 mg up to 1000 mg.
Study NCT04306146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Capsules
Study NCT02975791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Marking the cricothyroid membrane after ultrasound
Description: Ultrasonography is applied to the subjects neck in order to identify the cricothyroid membrane - subsequently the membrane is marked with a pen
Study NCT02975791 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Marking of the cricothyroid membrane after Palpation
Description: Palpation is applied to the subjects neck in order to identify the cricothyroid membrane- subsequently the membrane is marked with a pen
Study NCT01765790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
Description: * Dosing every 2 weeks~* Intravenous injection
Study NCT01765790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
Description: * Dosing weekly~* Intravenous injection
Study NCT03638921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEOPA
Description: Patients included in the study will receive MEOPA with a high concentration mask (bottle stored for at least 48 hours horizontally) at a minimum flow rate of 10 L / min under supervision of a health care worker after explanation of use to the patient in a quiet environment (box). MEOPA will be administered for a maximum total duration of 20 minutes, continuously or not depending on the needs of the patient, but after a continuous phase at the beginning of treatment of at least 3 minutes.
Study NCT00583947 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: arformoterol
Description: Arformoterol is given at a 7.5 ug per dosing during the cross-over phase and 15 ug per dosing during the open-label phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
Study NCT00583947 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: levalbuterol
Description: Levalbuterol is given at a 0.63 mg per dosing during the cross-over phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
Study NCT04568863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin intravenous
Description: 7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.
Study NCT04568863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intravenous
Description: 7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.
Study NCT04246398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMT
Description: Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake.~Each capsule will be taken with a sip of water, Capsules must not be crushed, chewed, or dissolved Participants will be evaluated for 15 minutes immediately following capsule administration.
Study NCT04246398 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: FMT - placebo
Description: Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake.~Each capsule will be taken with a sip of water, Capsules must not be crushed, chewed, or dissolved Participants will be evaluated for 15 minutes immediately following capsule administration.
Study NCT01972997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish
Study NCT01398696 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient Information Leaflets
Description: Patient Information Leaflets (PIL) about adult gastroenteritis, children gastroenteritis, adult pharyngitis or either children pharyngitis in consultation room
Study NCT01398696 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: usual consultation
Description: No particular intervention during consultation for the Patient. No Information Leaflets (PIL) is given
Study NCT05129410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 1. Prednisone 0.5-1.0 mg/kg/d, the dose was gradually reduced, and after 4 weeks, the dose was reduced by 5mg every two weeks, and then reduced to 10mg/d for 4-6 months after oral administration for 3 months, and then reduced to 7.5mg/d for maintenance therapy until 12 months;~2. MMF1.5g-2.0g/d
Study NCT00809679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-62 Dose 1
Description: Capsule dosage form 100 mg bid
Study NCT00809679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-62 Dose 2
Description: Capsule dosage form 200 mg bid
Study NCT00809679 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule dosage form placebo bid